ArticleJournal of applied microbiology2022
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.
Article in Journal of applied microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.Frontiers in immunology · 2022Trial
- IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.Archives of microbiology · 2026Review
- Purification and Characterization of Immunoglobulin Y (IgY) Targeting Surface Antigen 1 (SAG1) ofAntibodies (Basel, Switzerland) · 2025Article
- Egg yolk-derived phosvitin as a natural chelator:Veterinary world · 2025Article
- Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025Review
- Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections.Frontiers in immunology · 2025Review
- Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2 in Syrian Hamster Models.Vaccines · 2024Article
- Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters.Biological research · 2024Article
- The Chicken Egg: An Advanced Material for Tissue Engineering.Biomolecules · 2024Review
- Polyclonal anti-whole cell IgY passive immunotherapy shields against P. aeruginosa-induced acute pneumonia and burn wound infections in murine models.Scientific reports · 2024Article
- Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Use of Immunoglobulin Y Antibodies: Biosensor-based Diagnostic Systems and Prophylactic and Therapeutic Drug Delivery Systems for Viral Respiratory Diseases.Current topics in medicinal chemistry · 2024Review
- Novel extraction technologies and potential applications of egg yolk proteins.Food science and biotechnology · 2023Review
- Article
- Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.International immunopharmacology · 2022Article
- IgY Antibodies as Biotherapeutics in Biomedicine.Antibodies (Basel, Switzerland) · 2022Review
- Antiviral Immunoglobulins of Chicken Egg Yolk for Potential Prevention of SARS-CoV-2 Infection.Viruses · 2022Article
- Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?Viruses · 2022Article
- Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.Journal of applied microbiology · 2022Article
- Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus.AMB Express · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
aimsCOVID-19 pandemic caused by SARS-CoV-2 has become a public health crisis worldwide. In this study, we aimed at demonstrating the neutralizing potential of the IgY produced after immunizing chicken with a recombinant SARS-CoV-2 spike protein S1 subunit. METHODS AND
resultsE. coli BL21 carrying plasmid pET28a-S1 was induced with IPTG for the expression of SARS-CoV-2 S1 protein. The recombinant His-tagged S1 was purified and verified by SDS-PAGE, Western blot and biolayer interferometry (BLI) assay. Then S1 protein emulsified with Freund's adjuvant was used to immunize layer chickens. Specific IgY against S1 (S1-IgY) produced from egg yolks of these chickens exhibited a high titer (1:25,600) and a strong binding affinity to S1 (K
conclusionsWe demonstrated here that after immunization of chickens with our recombinant S1 protein, IgY neutralizing antibodies were generated against the SARS-CoV-2 spike protein S1 subunit; therefore, showing the potential use of IgY to block the entry of this virus. SIGNIFICANCE AND IMPACT OF THE STUDY: IgY targeting S1 subunit of SARS-CoV-2 could be a promising candidate for pre- and post-exposure prophylaxis or treatment of COVID-19. Administration of IgY-based oral preparation, oral or nasal spray may have profound implications for blocking SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.